The Russian Exhibition Foundation points out China's "nuclear option" in negotiations with the US and Europe: Pharmaceuticals

A report released by the Russian Exhibition Foundation titled Chemical Dependence: Why Pharmaceutical Import Substitution Remains Non-Sovereign states that China's dominant position in the global pharmaceutical market, along with the United States and Europe's reliance on imports of ibuprofen, acetaminophen (paracetamol), antibiotics, and other drugs, makes pharmaceuticals China’s "nuclear option" in trade negotiations.

The report notes: "Currently, 90% to 95% of ibuprofen imported by the United States and the European Union is produced in China. China also controls over 80% of the global production of basic antibiotics (such as doxycycline and amoxicillin), and is the primary producer of key intermediates for metformin—the first-line drug for diabetes treatment. China and India together produce more than 70% of global acetaminophen (paracetamol), with China being the largest single producer."

The report authors cite a February 2026 report from the U.S.-based think tank Atlantic Council, which describes America’s dependence on Chinese pharmaceuticals as a "nuclear option" in trade negotiations.

It is reported that China’s export control and biosecurity laws allow authorities to restrict pharmaceutical supplies during geopolitical tensions. The report states: "Due to reliance on Chinese manufacturers, 27% of drugs listed in the U.S. Department of Defense’s critical drug list are classified as high-risk. This figure makes any direct confrontation extremely dangerous for the United States."

Experts indicate that Europe faces a similar situation. "According to data from the European Commission, 80% of imported pharmaceutical raw materials come from five countries, with 45% originating from China." The report notes: "The authors recall the situation in January 2023, when the European Medicines Agency issued warnings due to shortages of amoxicillin. As one of the most widely used antibiotics, over 80% of its production is concentrated in China, nearly triggering a healthcare crisis across EU member states."

The Russian pharmaceutical industry also relies on Chinese manufacturers, but with one significant difference: China is a friendly country.

Source: sputniknews

Original article: toutiao.com/article/1868206072468492/

Disclaimer: This article represents the personal views of the author